Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[MIRABEGRON--A NEW DRUG FOR TREATMENT OF OVERACTIVE BLADDER].

G R Kasjan

    Urologiia (Moscow, Russia : 1999)
    |December 16, 2015
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [NOCEBO EFFECT: AN ADVICE TO A PRACTITIONER].

    Urologiia (Moscow, Russia : 1999)·2015
    Same journal

    [Resolution of the consensus council on the management of patients with urinary tract infection].

    Urologiia (Moscow, Russia : 1999)·2026
    Same journal

    [Male infertility and reproductive dysfunction: clinical aspects of the use of terms and definitions from the Russian Society of Urology guidelines].

    Urologiia (Moscow, Russia : 1999)·2026
    Same journal

    [The use of augmented reality technologies in urological practice].

    Urologiia (Moscow, Russia : 1999)·2026
    Same journal

    [Modern concepts of pathogenesis, ethological factors and diagnosis of viral cystitis].

    Urologiia (Moscow, Russia : 1999)·2026
    Same journal

    [Chronic recurrent cystitis: analysis of the current state of the problem].

    Urologiia (Moscow, Russia : 1999)·2026
    Same journal

    [Sex disparities of urolithiasis: epidemiological features and possible causes].

    Urologiia (Moscow, Russia : 1999)·2026
    See all related articles

    Mirabegron, a novel beta-3 adrenergic agonist, offers a new oral treatment for overactive bladder (OAB). It effectively manages urinary incontinence, urgency, and frequency with a favorable safety profile.

    Area of Science:

    • Pharmacology
    • Urology

    Context:

    • Overactive bladder (OAB) is a common condition affecting both men and women.
    • Current treatments, such as anticholinergics, have limitations and side effects.
    • Mirabegron represents a new therapeutic class for OAB management.

    Purpose:

    • To introduce Mirabegron, a beta-3 adrenergic agonist, as a novel oral therapy for overactive bladder (OAB).
    • To highlight its approval and clinical indications for OAB symptoms including urge urinary incontinence, urgency, and urinary frequency.
    • To present Mirabegron as an alternative for patients unresponsive to or intolerant of anticholinergic medications.

    Summary:

    • Mirabegron is the first oral beta-3 adrenergic agonist approved for OAB treatment.
    • It addresses key storage symptoms like incontinence, urgency, and frequency in both genders.

    Related Experiment Videos

  • Clinical trials demonstrate its efficacy in patients previously treated with anticholinergics.

    • Impact:

    • Mirabegron provides a new pharmacological option for managing overactive bladder.
    • Its distinct mechanism of action and favorable safety profile offer an alternative to existing therapies.
    • The drug's approval signifies a significant advancement in the treatment of urination disorders.